RESEARKA

The cited A/B receipts support a specific working claim: rapamycin at 42 ppm extended female median lifespan by 26%; rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Citation Support

• source_1 Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
• source_2 Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
• source_3 Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer
• source_4 Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
• source_5 Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging